September, 2019 | PharmaShots

Celltrion Reports Results of CT-P10 (rituximab, biosimilar) in P-III for Advance Follicular Lymphoma (AFL)

Celltrion Signs an Exclusive Co-Marketing Agreement with Juno in Australia

September 30, 2019October 1, 2019Shiwani Sharma

Shots: Juno to provide sales promotion and hospital contracting services to Australian Hospital market customers and will co-market Herzuma (biosimilar, trastuzumab) and Truxima [Read More...]

Vertex Collaborates with Ribometrix to Discover and Develop up to Three RNA Targeted Candidates

September 30, 2019September 30, 2019Shiwani Sharma

Shots: Ribometrix to get $20M up front including an equity investment in the company with $700M as development, regulatory and commercial milestones and [Read More...]

Merck’s Recarbrio (imipenem/cilastatin/relebactam) Receives the US FDA’s Approval for Complicated Urinary Tract and Complicated Intra-Abdominal Bacterial Infections

Merck Reports Results of Recarbrio (imipenem/cilastatin/relebactam) in P-III RESTORE-IMI 2 Study for Patients with HABP/VABP

September 30, 2019September 30, 2019Shiwani Sharma

Shots: The P-III RESTORE-IMI 2 study involves assessing of Recarbrio (imipenem 500 mg, cilastatin 500 mg, and relebactam 250 mg) vs Piperacillin/Tazobactam in [Read More...]

GSK Reports Results of Nucala (mepolizumab) in REALITI-A Study for Severe Eosinophilic Asthma

September 30, 2019September 30, 2019Shiwani Sharma

Shots: The REALITI-A study involves assessing of Nucala (100mg, SC) in 368 patients with severe eosinophilic asthma, being conducted in a routine care [Read More...]

Roche’s Rituxan (rituximab) Receives the US FDA’s Approval for Two Rare Blood Vessel Disorders in Pediatric Patients Aged 2yrs. and Above

September 30, 2019September 30, 2019Shiwani Sharma

Shots: The FDA’s approval is based on P-IIa PePRS study assessing MabThera/Rituxan (IV) + glucocorticoids in 25 pediatric patients with active granulomatosis with [Read More...]

Sobi to Acquire Dova Pharmaceuticals for $915M

September 30, 2019October 3, 2019Shiwani Sharma

Shots: Sobi acquires Dova Pharmaceutical in cash & stock transaction making a total deal value as $915M. Dova to receive upfront of $27.50/share [Read More...]

PharmaShots Weekly Snapshot (September 23– 27, 2019)

September 30, 2019October 11, 2019Shiwani Sharma

1. Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma Published: Sept 27, 2019 | Tags: [Read More...]

Incyte Reports Updated Results of Pemigatinib in P-II FIGHT-202 Trial for Patients with Previously Treated Advanced Cholangiocarcinoma

September 27, 2019February 13, 2020Shiwani Sharma

Shots: The P-II FIGHT-202 (NCT02924376) study involves assessing of pemigatinib (13.5 mg, qd) as monothx in adults patients previously treated, LA or metastatic [Read More...]

Pfizer Reports Results of PF-05280586 (rituximab biosimilar) in REFLECTIONS B328-06 study for CD20-Positive Non-Hodgkin Lymphoma

Pfizer Reports Results of Abrocitinib in P-III JADE MONO-2 Study for Moderate to Severe Atopic Dermatitis

September 27, 2019February 13, 2020Shiwani Sharma

Shots: The P-III JADE MONO-2 study involves assessing of Abrocitinib (qd, 100mg & 200mg) vs PBO in 391 patients with mod. to sev. [Read More...]

Top 20 Acquisitions of 2018 Based on the Total Deal Value

Top 20 Biopharma Acquisitions of 2018 Based on the Total Deal Value

September 27, 2019February 13, 2020Shiwani Sharma

Biopharma acquisition activity in 2018 shows a significant increase over the previous year. Takeda proved to be on top with the acquisition of [Read More...]